Ciprocopan China approval gives PNH patients a new once-daily oral Factor B treatment option
Nuvectis Pharma’s ciprocopan wins China approval for PNH. Read how the once-daily Factor B drug could reshape the global treatment race.
Pharma & Biotech
Pharma & Biotech
Why Royalty Pharma is betting up to $425m on Neurimmune’s Phase 3 heart drug
Neurimmune sells part of its cliramitug royalty to Royalty Pharma for up to $425 million as the ATTR-CM antibody advances through Phase 3.
Pharma & Biotech
Ionis Pharmaceuticals shares slide as eplontersen misses key heart disease endpoint
See why the CARDIO-TTRansform miss complicates eplontersen’s ATTR-CM path and tests gene silencing on top of stabilizer therapy.
Medical Devices & Diagnostics
How the NeoGenomics PTEN IHC test supports targeted prostate cancer treatment
NeoGenomics launches an FDA-approved PTEN IHC companion diagnostic to identify prostate cancer patients eligible for AstraZeneca’s Truqap.
Pharma & Biotech
Why Sino Biopharmaceutical’s twin respiratory deals may worry global pharma rivals
Sino Biopharmaceutical Limited has secured two respiratory medicine transactions involving AstraZeneca PLC and GSK plc, strengthening both its out-licensing and China commercialization strategy. Its subsidiary Chia Tai Tianqing Pharmaceutical Group granted AstraZeneca exclusive rights outside China to develop, manufacture and commercialize TQC3721, an investigational PDE3/4 inhibitor for chronic respiratory disease, while separately obtaining mainland China
Pharma & Biotech
AstraZeneca adds Abbisko’s lumipodlin to expanding Tagrisso combination strategy
Discover why Abbisko and AstraZeneca are testing oral PD-L1 inhibitor lumipodlin with Tagrisso in EGFR-mutated lung cancer.
Medical Devices & Diagnostics
Enhertu wins EU tumor-agnostic approval, but HER2 testing will decide its real impact
The European approval takes Enhertu beyond organ-specific oncology, although its clinical reach will depend on reliable HER2 testing, reimbursement and safety management.
Features & Analysis
AstraZeneca and YMCA target the overlooked barriers delaying cancer screening in America
AstraZeneca is funding a five-year YMCA cancer initiative that will begin in 75 communities, but its impact will depend on whether education leads to completed screenings, clinical referrals and sustained survivor support.
Pharma & Biotech
Datroway nears EU first-line approval for metastatic triple-negative breast cancer
Discover how Datroway’s EU recommendation could reshape first-line treatment for metastatic triple-negative breast cancer. Read the analysis.
Pharma & Biotech
AstraZeneca’s Imfinzi gains a first-mover edge in high-risk non-muscle-invasive bladder cancer
Imfinzi has FDA approval with BCG in early high-risk bladder cancer. The next test is adoption, recurrence data and real-world use.